Limited data are available on long-term clinical outcomes regarding the switch from Remicade
To investigate long-term efficacy, safety, pharmacokinetic profile, and immunogenicity.
We performed a single-center prospective observational cohort study following an elective switch from Remicade
Eighty-three patients were included (57 Crohn's disease, 24 ulcerative colitis, and 2 IBD unclassified), and 68 patients completed one-year follow-up. Disease activity (Harvey-Bradshaw Index and Simple Clinical Colitis Activity Index) as well as inflammatory markers (CRP, fecal calprotectin) did not change significantly during the 1-year follow-up. In total, 7 out of 83 patients (8%) demonstrated detectable antidrug antibodies during follow-up, and 5 out of 7 antidrug antibody titers were already detectable at baseline prior to switching. Six patients (7%) discontinued CT-P13 due to adverse events.
Following a switch from Remicade